Thromboembolic risk in dermatomyositis patients treated with intravenous immunoglobulin: a retrospective cohort study

Supplementary data for "Thromboembolic risk in dermatomyositis patients treated with intravenous immunoglobulin: a retrospective cohort study."

Method S1: Intravenous immunoglobulin (IVIg) definition
Method S2 : Exclusion criteria
Method S3: Flow diagram of study design
Method S4: Matching and propensity score plots
Analysis SI: Analysis requiring >2 DM diagnoses for study inclusion: baseline characteristics
Analysis SII: Analysis requiring >2 DM diagnoses for study inclusion: propensity score plots
Analysis SIII: Analysis requiring >2 DM diagnoses for study inclusion: IVIg vs. non-IVIg systemic and IVIg vs. non-systemic treatment
Analysis SIV: Analysis of TE events up to 6 months following IVIg: baseline characteristics
Analysis SV: Analysis of TE events up to 6 months following IVIg: propensity score plots
Analysis SVI: Analysis of TE events up to 6 months following IVIg: IVIg vs. non-IVIg systemic and IVIg vs. non-systemic treatment